#Moderna
-

Moderna Stock Hits 52-Week High as Q3 Profit Beat Lifts Shares, but Q4 Revenue Outlook Softens
Moderna shares climbed to a new 52-week high after the company posted an unexpected third-quarter profit and raised full-year revenue…
-

IDNA ETF Surges as Moderna Trial Data Adds Nearly 12 NAV Points
The iShares Genomics Immunology and Healthcare ETF was reshaped by a single clinical catalyst after Moderna and Merck rallied sharply…
-

Moderna Stock Soars 93% After Phase 3 Melanoma Trial Win
Moderna shares nearly doubled after a positive Phase 3 readout for its personalized melanoma therapy with Merck. The rally added…
-

Moderna Ebola Vaccine Deal: CEPI Commits Up to $50 Million
Moderna has secured up to $50 million from CEPI to accelerate development of an Ebola vaccine as infections rise in…